Raymond James Initiates Strong Buy on Taysha (TSHA) Amid Rett Syndrome Trial Momentum

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of billionaire Steve Cohen’s small-cap stock picks with huge upside potential. On October 20, Raymond James initiated coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Strong Buy rating and a $13 price target, aligning with the broader analyst consensus.

The firm cited promising Phase 1/2 REVEAL trial results for Rett syndrome and positive FDA feedback as key drivers. With a $1.28 billion market cap and a cash-rich balance sheet, Taysha is well-positioned to advance its clinical programs.

Recent milestones include Breakthrough Therapy Designation, FDA protocol alignment, and approval for a 6-month interim analysis that could fast-track regulatory submission. Patient enrollment for REVEAL Part B is underway, with final dosing expected by mid-2026 and potential commercialization in 2027. Taysha’s focus on a genetically defined Rett syndrome population offers a clear therapeutic opportunity.

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is a clinical-stage biotech firm dedicated to advancing adeno-associated virus (AAV)-based gene therapies for rare, single-gene disorders affecting the central nervous system. Its mission centers on delivering targeted treatments that address the root genetic causes of these conditions.

While we acknowledge the potential of TSHA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Stocks to Buy As Gold Rallies and 13 Stocks to Buy According to Billionaire Ray Dalio’s Bridgewater Associates.

Disclosure: None. This article is originally published at Insider Monkey.